Literature DB >> 12542794

Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic.

M L M Andersen1, M Ruhwald, M H Nissen, S Buus, M H Claesson.   

Abstract

Thirty self-peptides were selected on the basis of their predicted binding to H-2b molecules. The binding of peptides was ascertained experimentally by biochemical (KD measurements) and cellular [major histocompatibility complex class I (MHC-I) stabilization] assays. A weak, but significant, correlation between KD measurements and MHC-I stabilization was observed. Mice (n = 99) were immunized with individual peptides. Twenty-eight peptides were found to induce peptide-specific cytotoxic activity, and a total of 84 mice developed significant cytotoxic T lymphocyte (CTL) responses after immunization. Only one of the 21 mice immunized with high-affinity peptides developed a peptide-specific CTL response of 29 lytic units per 106 splenocytes, whereas 11 of the 42 mice immunized with intermediate-affinity peptides developed peptide-specific CTL responses at this level (P < 0.05). These observations suggest the absence of tolerance towards most MHC-I-restricted self-peptides and that strong antiself immunity can be generated preferentially towards self-peptides with an intermediate affinity for MHC-I. These data should be considered in the design of tumour vaccines based on MHC-I-binding self-peptides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12542794     DOI: 10.1046/j.1365-3083.2003.01182.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.

Authors:  Christopher D Zahm; Viswa T Colluru; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-06-20       Impact factor: 11.151

2.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

3.  Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors:  David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

4.  A cell-based MHC stabilization assay for the detection of peptide binding to the canine classical class I molecule, DLA-88.

Authors:  Peter Ross; Jennifer C Holmes; Gregory S Gojanovich; Paul R Hess
Journal:  Vet Immunol Immunopathol       Date:  2012-09-21       Impact factor: 2.046

5.  Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes.

Authors:  Marie Louise Andersen; Morten Ruhwald; Mette Thorn; Anders Elm Pedersen; Susanne Mathiassen; Soren Buus; Mogens H Claesson
Journal:  J Immune Based Ther Vaccines       Date:  2003-01-29

6.  Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE.

Authors:  Yi-Hsiang Huang; Masaki Terabe; C David Pendleton; Deborah Stewart Khursigara; Tapan K Bera; Ira Pastan; Jay A Berzofsky
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

7.  Ovine and murine T cell epitopes from the non-structural protein 1 (NS1) of bluetongue virus serotype 8 (BTV-8) are shared among viral serotypes.

Authors:  José M Rojas; Lourdes Peña; Verónica Martín; Noemí Sevilla
Journal:  Vet Res       Date:  2014-03-12       Impact factor: 3.683

8.  AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma.

Authors:  Giuseppina Conteduca; Daniela Fenoglio; Alessia Parodi; Florinda Battaglia; Francesca Kalli; Simone Negrini; Samuele Tardito; Francesca Ferrera; Annalisa Salis; Enrico Millo; Giuseppe Pasquale; Giusi Barra; Gianluca Damonte; Francesco Indiveri; Soldano Ferrone; Gilberto Filaci
Journal:  Oncotarget       Date:  2016-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.